NVAX Vaccine Called "Best-in-Class"

The Dow was last seen down over 400 points

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

1/29/2021 Have you seen our volatility scorecard? Sign up by clicking here! Vaccine Data, Speculative Trading Drama Sink Stocks By: Fernanda Horner Stocks are falling once again on Friday afternoon after Johnson & Johnson's (JNJ) one-dose Covid-19 vaccine results failed to impress investors. The Dow Jones Industrial Average (DJI) was down roughly 400 points at midday, while the Nasdaq Composite (IXIC) and S&P 500 Index (SPX) were also suffering considerable losses. Traders are still concerned about ramped up speculative trading activity, with shares of GameStop (GME) surging back up after Robinhood allowed limited buying of heavily shorted stocks -- just a day after drawing criticism for restricting them. Meanwhile, the Securities and Exchange Commission (SEC) announced it would investigate the online brokerage firm's actions to determine whether or not it harmed investors.  Continue reading for more on today's market, including: Analyst says NVAX's Covid-19 vaccine is "best-in-class." Caterpillar stock gets a boost from its Q4 earnings beat. Plus, options bulls target BIIB on FDA extension; ALUS pops after combining with clean energy developer; and golf stock plummets on underwritten public offering. Share on Read More...       Breaking: Tesla is dead. Elon Musk is ruined. Thanks to a new discovery known as "Blue Gas," companies like Tesla are on their deathbed. "Blue Gas" is 100% emission free and allows cars to fully charge in just minutes. Discover the $3 stock that is driving the industry. Get in NOW. Sponsored In Case You Missed It... Blue-Chip Pharma Stock Dips on Vaccine Update Johnson & Johnson's coronavirus vaccine was found to be 66% effective in a global study Q4 Earnings, Revenue Beat Boosts Caterpillar Stock Caterpillar is making moves to close Wednesday's broad-market bear gap NVAX Surges After Analyst Calls Covid-19 Vaccine "Best-in-Class" The security earned a price-target hike to $295 from $215 this morning Options Traders Pile on Biogen Stock Following FDA Update The FDA extended the review period for Biogen's Alzheimer treatment The "Tesla Killer" is here... Thanks to a new discovery known as "Blue Gas", companies like Tesla are about to go down in flames. "Blue Gas" is 100% emission free and allows cars to fully charge in just minutes. Discover the $3 stock that is driving the industry. Get in NOW. Sponsored Want More Minute-to-Minute Updates? Ranking the most volatile stocks → Schaeffer's Volatility Scorecard Before the market opens → Opening View After the market close → Market Recap Last week's rundown → 5 Minute Market Rundown Analyzing the current market climate → Monday Morning Outlook What's on our CEO's radar this week → Chart of the Week Schaeffer's has a podcast, have you given us a listen?       ADVERTISE // CAREERS // SHOP Be sure to add us to your contacts so you don't miss out on any news! Unsure of how to do that? Follow our instructions located here. For more information about our privacy practices, please review our Privacy Policy or our Terms & Conditions. 5151 Pfeiffer Road Cincinnati, OH 45242 If you didn't create an account using this email address or no longer wish to receive these emails, please unsusbscribe here.